REVIEW ON PHARMACOVIGILANCE STUDY OF TELMISARTAN IN HYPERTENSION PATEINTS

Authors

  • DABHADE SUHAS Department of Pharmacology, M.G.M’s. Medical College, N-6, Cidco Aurangabad-431 003, Maharashtra.
  • BHOSLE DEEPAK Department of Pharmacology, M.G.M’s. Medical College, N-6, Cidco Aurangabad-431 003, Maharashtra
  • ATRE KAVITA Department of Pharmacology, M.G.M’s. Medical College, N-6, Cidco Aurangabad-431 003, Maharashtra

Keywords:

Hypertension, Pharmacovigilance, Adverse Drug Reactions, Telmisartan

Abstract

Hypertension is a chronic condition in which blood pressure is higher than normal range. For treatment of hypertension, a broad range of antihypertensive medication is currently available, choice is depend upon where cheaper ones would be equally effective, may have negative impacts on national healthcare budgets.  Antihypertensive drugs are frequently  associated with adverse drug reactions (ADRs) that may limit treatment options and reduce patient adherence, which may hinder blood pressure control. These drugs are believed to cause ADRs or symptoms that make patients feel worse than they did before beginning drug therapy for their "asymptomatic" disease. The science and systems used for systematically identifying and correlating drugs and side-effects and taking corrective actions fall under the discipline of Pharmacovigilance.

Key words: Hypertension, Pharmacovigilance, Adverese Drug Reactions, Telmisartan.

Downloads

Download data is not yet available.

References

. Chobanian AV, Bakris GL, Black HR et al. "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure". JAMA. 2003;290(2):197.

. Dhikav V, Singh S, Anand KS. Adverse drug reaction monitoring in India. J Indian Acad Clin Med. 2004;5:27–3.

. Burt V, Whelton P, Rocella E, Brown C, Cutler J. Prevalence of hypertension in the US population: results from the third national health and nutrition examination survey, 1988-1991. Hypertension 1995;25:305–13.

. Carretero OA, Oparil S. "Essential hypertension. Part I: definition and etiology". Circulation .2000;101(3):329–335.

http://www.cvphysiology.com/Blood%20Pressure/BP023.htm Cardiovascular Physiology ConceptsRichard E. Klabunde, PhD. Revised 04/12/2012. Retrive 03/03/2013

. Nelson MR, McNeil JJ, Peeters A et al. PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994–1998. Med J Aust. 2001;174(11):565–568.

. Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. In: Strom BL, editor.Pharmacoepidemiology. 3rd ed. Chichester: John Wiley and Sons, Ltd.; 2000.151–174.

. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437–443.

Rockville MD. Guidance for Industry Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. U.S. FDA; 2005;325-397.

ICH E2E: Guideline pharmacovigilnace planning.

Satoskar RS, Bhandarkar SD and Ainapure SS. Pharmacology and Pharmacotherapeutics. 16th ed. Popular Prakashan; 82-85.

Lazarou J, Pomeranz BH, Corey PN. Incidence of adversedrug reactions in hospitalised patients: a meta-analysis ofprospective studies. JAMA 1998; 279 (15): 1200-5.

Bates DW. Spell N, Cullen DJ et al. The costs of adverse drug reactions in hospitalised patients. JAMA 1997; 277: 301-07.

Leape LL. Errors in medicine. JAMA 1994; 272: 1851-7.

Bates DW, Collen DJ, laird N et al. Incidence of adverse drug events and potential adverse drug events in hospitalized patients. JAMA 1997; 277: 307-11.

Edwards IR. The accelerating need for pharmacovigilance. J R Coll Physicians Lond. 2000 Jan-Feb;34(1):48-51.

http://www.swissmedic.ch/marktueberwachung/00091/00136/00137/index.html?lang=en, updated 26/01/2010. Retrieve 03/03/2013

V. Raghu Kumar, V. Raghu Ram, B. Guru Prasad, G. P Mohanta and P.K Manna. A study of adverse drug reactions due to antihypertensive drugs in a tertiary care teaching hospital. Int. J. of Pharm. & Life Sci. 2011; 2(5): 767-772

Leape LL. Errors in medicine. JAMA 1994; 272: 1851-7.

Sriram S, Ghasemi A, Ramasamy R, Devi M, Balasubramanian R, Ravi TK, et al.: Prevalence of adverse drug reactions at a private tertiary care hospital in south India. J Res Med Sci 2011, 16:16-25.

http://www.clinicalresearchsociety.org/forum/pharmacovigilance/case-processing-in-pharmacovigilance/msg37466/#msg37466. 25/04/2011. Retrieve 03/03/2013

Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281 (9): 824-9.

McClellan KJ , Markham A. Telmisartan. Drugs.1998;56(6):1039-1044.

Micardis. Summary of Product Characteristics, Dec 1998.

Meredith PA. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. Am J Cardiovasc Drugs. 2005;5:171–83.

Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press. 2001;10(1):6–11.

Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens. 2002;16(Suppl 2):S13–16.

Wienen W, Entzeroth M, van Meel JCA, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev. 2000;18:127–56.

Takai S, Kirimura K, Jin D, et al. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res. 2005;28:593–600.

http://hypertension.emedtv.com/telmisartan/telmisartan-dosing-p2.html, Written by/reviewed by: Kristi Monson, PharmD; Arthur Schoenstadt, MD, Last reviewed by: Kristi Monson, PharmD Last updated/reviewed: 07/12/2009. Retrieve 03/03/2013.

. http://hypertension.emedtv.com/telmisartan/telmisartan-side-effects-p2.html,Written by/reviewed by: Kristi Monson, PharmD; Arthur Schoenstadt, MD Last reviewed by: Kristi Monson, PharmD Last updated/reviewed: 03/01/2007. Retrieve date 03/03/2013.

Smith DHG et al. Once daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther, Jul/Aug 1998;15(4):229-240.

Karlberg BE et al. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens. 1999;17:293-302.

Neutel JM et al. Comparison of telmisartan with lisinopril in patients with mild to moderate hypertension. Am J Therap. 1999;6:161-166.

Lacourciere Y et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers Telmisartan and amlodipine. Blood Press Monit.1998;3:295-302.

Mallion JM et al. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild to moderate hypertension. J Human Hypertens.1999;13:657-664.

Published

01-07-2013

How to Cite

SUHAS, D., B. DEEPAK, and A. KAVITA. “REVIEW ON PHARMACOVIGILANCE STUDY OF TELMISARTAN IN HYPERTENSION PATEINTS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 6, no. 3, July 2013, pp. 17-20, https://mail.innovareacademics.in/journals/index.php/ajpcr/article/view/172.

Issue

Vol 6 Issue 3 (July-Sept) 2013

Section

Articles

The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.